|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500107792 |
|
最近更新日期: Date of Last Refreshed on: |
2025-08-19 08:58:36 |
|
注册时间: Date of Registration: |
2025-08-19 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
博乐达30%超分子水杨酸联合黄金射频微针治疗敏感皮肤综合征的安全性和有效性临床研究 |
|
Public title: |
Clinical Study on the Safety and Efficacy of Broda 30% Supramolecular Salicylic Acid Combined with Gold Microneedle Radiofrequency for the Treatment of Sensitive Skin Syndrome |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
博乐达30%超分子水杨酸联合黄金射频微针治疗敏感皮肤综合征的安全性和有效性临床研究 |
|
Scientific title: |
Clinical Study on the Safety and Efficacy of Broda 30% Supramolecular Salicylic Acid Combined with Gold Microneedle Radiofrequency for the Treatment of Sensitive Skin Syndrome |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
朱晓莹 |
研究负责人: |
潘忠兰 |
|
Applicant: |
Xiaoying Zhu |
Study leader: |
Zhonglan Pan |
|
申请注册联系人电话: Applicant telephone: |
+86 135 4437 3935 |
研究负责人电话:
Study leader's |
+86 182 6263 6589 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xyzhu.s@broda.cn |
研究负责人电子邮件: Study leader's E-mail: |
1239234175@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市浦东新区民生路1518号金鹰大厦B座402B室 |
研究负责人通讯地址: |
江苏省南京市鼓楼区江东北路88号,清江苏宁广场601A |
|
Applicant address: |
Room 402B, Tower B, Golden Eagle Building, No. 1518 Minsheng Road, Pudong New Area, Shanghai |
Study leader's address: |
No. 88, East Jiang North Road, Gulou District, Nanjing, Jiangsu. Qing Jiangsu Nanjing Plaza, Room 601A |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
210000 | |
|
申请人所在单位: |
上海乐邦达医药科技有限公司 |
||
|
Applicant's institution: |
Shanghai Lebangda Pharmaceutical Technology Co., Ltd. |
||
|
研究负责人所在单位: |
南京懿佳医疗美容门诊部 |
||
|
Affiliation of the Leader: |
Nanjing Yijia Aesthetic Clinic |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审2025-002 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京懿佳医疗美容门诊部医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Nanjing Yijia Medical Aesthetics Clinic Medical Ethics Review Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-11 00:00:00 | ||
|
伦理委员会联系人: |
潘忠兰 |
||
|
Contact Name of the ethic committee: |
Zhonglan Pan |
||
|
伦理委员会联系地址: |
江苏省南京市鼓楼区江东北路88号,清江苏宁广场601A |
||
|
Contact Address of the ethic committee: |
No. 88, East Jiang North Road, Gulou District, Nanjing, Jiangsu. Qing Jiangsu Nanjing Plaza, Room 601A |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 182 6263 6589 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京懿佳医疗美容门诊部 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing Yijia Aesthetic Clinic |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市鼓楼区江东北路88号,清江苏宁广场601A |
||||||||||||||||||||||
|
Primary sponsor's address: |
Jiangsu Province, Nanjing City, Gulou District, No. 88 Jiangdong North Road,Qingjiang Suning Plaza, Room 601A |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海乐邦达医药科技有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Lebangda Pharmaceutical Technology Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
敏感皮肤综合征 |
||||||||||||||||||||||
|
Target disease: |
Sensitive Skin Syndrome |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评价30%超分子水杨酸联合黄金射频微针治疗敏感皮肤综合征的安全性和有效性 |
||||||||||||||||||||||
|
Objectives of Study: |
Clinical Study on the Safety and Efficacy of Broda 30% Supramolecular Salicylic Acid Combined with Gold Microneedle Radiofrequency for the Treatment of Sensitive Skin Syndrome |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
治疗方案 1)两组受试者均先清洁面部,拍摄VISIA全光源照片和单反照片(正面、左侧、右侧),对皮损进行评价。 2)面部局部麻醉:外敷麻膏(以机构常用品牌为主),表面麻醉50-60分钟,可先用维生素E乳预处理。 3)方案 A、试验组:受试者麻醉后先行涂抹一支博乐达30%超分子水杨酸(7g/支)五分钟(无需稀释及完全渗透),后进行黄金射频微针治疗,治疗结束后,即刻使用1支博乐达30%超分子水杨酸(7g/支)进行治疗。 居家使用:蓝润修护乳(商品名:蓝润医用愈肤生物膜膏剂敷料,提供单位:蓝科兴医疗科技(长春)有限公司)、2%超分子水杨酸(商品名:博乐达滋养调理面膜)、滋养保湿面膜(商品名:博乐达滋养保湿面膜),白天须遮蔽型防晒。 B、对照组:受试者麻醉后仅行黄金射频微针治疗。 居家:蓝润修护乳(商品名:蓝润医用愈肤生物膜膏剂敷料,提供单位:蓝科兴医疗科技(长春)有限公司)、保湿面膜(商品名:博乐达滋养保湿面膜),白天须遮蔽型防晒。 两组治疗结束后均即刻使用博乐达滋养保湿面膜15-20分钟。 4)操作方法 A、黄金射频微针操作方法:治疗深度1.2-2.5mm,F模式,能量4-7;建议根据受试者皮肤情况由研究者判断和操作,建议将能量设置为真皮网状层,操作至终点反应,皮肤呈现微粉色外观。 B、30%超分子水杨酸治疗操作方法:使用麻膏后即刻使用一支博乐达30%超分子水杨酸(7g/支)不稀释涂抹按摩5分钟,后即刻进行黄金射频微针。术后即刻将一支博乐达30%超分子水杨酸(7g/支)膏体均匀刷至受试者面部皮损处,可使用无菌注射用水按摩促进水杨酸的吸收,过程中可反复加水,观察直至水杨酸完全吸收,此过程不低于15分钟,治疗过程中如有不适可用风扇和冷喷减少刺激感,治疗结束后无需清洗,用博乐达滋养保湿面膜冷敷15-20分钟。 ⑤治疗频次:30%超分子水杨酸、黄金射频微针均每6周治疗1次,共治疗3次。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Treatment Plan 1) Both groups of subjects will first wash their face, and then take VISIA full-spectrum photos and DSLR photos (front, left side, and right side) to evaluate the skin lesions. 2) Local facial anesthesia: Apply topical anesthetic cream (mainly using brands commonly used at the institution) and allow surface anesthesia for 50-60 minutes. Vitamin E cream may be applied in advance for pre-treatment. 3) Treatment Protocol A. Experimental Group: After anesthesia, apply one tube of BoleDa 30% supramolecular salicylic acid (7g/tube) onto the skin and massage for five minutes (no dilution required and ensure complete penetration). Then proceed with gold radiofrequency microneedle treatment. Immediately after the treatment, apply one tube of BoleDa 30% supramolecular salicylic acid (7g/tube) to the treatment area. Home care: Use Lanrun Repairing Emulsion (brand name: Lanrun Medical Skin Healing Biofilm Ointment Dressing; provided by Lanke Xing Medical Technology (Changchun) Co., Ltd.), 2% supramolecular salicylic acid (brand name: BoleDa Nourishing and Conditioning Mask), and nourishing moisturizing mask (brand name: BoleDa Nourishing Moisturizing Mask). Use occlusive sun protection during the day. B. Control Group: After anesthesia, only perform gold radiofrequency microneedle treatment. Home care: Use Lanrun Repairing Emulsion (brand name: Lanrun Medical Skin Healing Biofilm Ointment Dressing; provided by Lanke Xing Medical Technology (Changchun) Co., Ltd.), and moisturizing mask (brand name: BoleDa Nourishing Moisturizing Mask). Use occlusive sun protection during the day. Immediately after treatment, both groups will apply BoleDa Nourishing Moisturizing Mask for 15-20 minutes. 4) Operating Procedures A. Gold Radiofrequency Microneedle Operation: Set the treatment depth between 1.2-2.5 mm, use F mode, and energy level between 4-7. The investigator should determine and operate according to the subject's skin condition, and it is recommended to adjust the energy to target the reticular dermis. Continue the operation until the endpoint reaction is achieved, indicated by a slight pinkish appearance of the skin. B. 30% Supramolecular Salicylic Acid Treatment Procedure: Immediately after applying the topical anesthetic cream, apply one tube of BoleDa 30% supramolecular salicylic acid (7g/tube) without dilution, and gently massage for 5 minutes. Proceed immediately with the gold radiofrequency microneedle treatment. Immediately after the procedure, evenly apply one tube of BoleDa 30% supramolecular salicylic acid (7g/tube) onto the lesion areas of the subject's face. Sterile water for injection may be used during massage to promote salicylic acid absorption. Water may be reapplied repeatedly during the process until complete absorption of the salicylic acid is observed. This process should last no less than 15 minutes. If discomfort occurs during the treatment, a fan or cold spray may be used to reduce irritation. No rinsing is required after the treatment; instead, apply BoleDa Nourishing Moisturizing Mask as a cold compress for 15-20 minutes. ⑤ Treatment Frequency: Both 30% supramolecular salicylic acid and gold radiofrequency microneedle treatments are scheduled once every six weeks, for a total of three sessions. |
||||||||||||||||||||||
|
纳入标准: |
1)敏感皮肤综合征诊断标准:皮肤受到外界轻微刺激时易出现灼热、阵发性潮红和/或刺痛、瘙痒及紧绷感等症状,伴或不伴持续性红斑;且经敏感量表评估(附件1),SS-7得分>=5分; 2)年龄 18岁至60岁; 3)受试者自愿参加本临床研究并签署书面知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) Diagnostic criteria for Sensitive Skin Syndrome: The skin easily exhibits symptoms such as burning, episodic flushing, and/or stinging, pruritus, and tightness upon mild external stimulation, with or without persistent erythema; AND a score of ≥5 on the SSS-7 Scale (Appendix 1). 2) Age between 18 and 60 years. 3) Participants voluntarily join this clinical study and provide written informed consent. |
||||||||||||||||||||||
|
排除标准: |
1)继发性敏感皮肤(如玫瑰痤疮、脂溢性皮炎、激素依赖性皮炎、接触性皮炎、特应性皮炎及肿胀性红斑狼疮等皮肤疾病常伴有皮肤敏感)可能影响对试验结果的判断; 2)已知对试验药品过敏者或高敏体质者; 3)妊娠、计划妊娠或哺乳期女性; 4)试验前4周内使用过:抗生素类药物(如米诺环素、多西环素)、β-肾上腺素能受体阻滞剂(如卡维地洛)、糖皮质激素、内分泌调节药物及其他系统用药(如羟氯喹等)者; 5)试验前2周内使用过夫西地酸乳膏、壬二酸、溴莫尼定等外用药物者; 6)试验前2周内接受过化学剥脱术治疗者; 7)试验前2个月内口服过维A酸类药物者(阿维A酸类药物6个月); 8)试验前3个月外用他克莫司者; 9)试验前2个月接受过面部光电、注射治疗(包括水光针)或手术治疗者; 10)情绪不稳定或对于试验预期效果期望值过高者; 11)瘢痕体质、畏针或不能配合随访者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Secondary sensitive skin (e.g., skin sensitivity associated with dermatoses such as rosacea, seborrheic dermatitis, steroid-induced dermatitis, contact dermatitis, atopic dermatitis, or lupus erythematosus tumidus) that may confound trial results; 2) Known allergy to the investigational product or hyperreactive constitution; 3) Pregnant, planning pregnancy, or lactating women; 4) Use of systemic medications within 4 weeks prior to the trial: antibiotics (e.g., minocycline, doxycycline), β-adrenergic blockers (e.g., carvedilol), corticosteroids, endocrine regulators, or other systemic drugs (e.g., hydroxychloroquine); 5) Topical application of fusidic acid cream, azelaic acid, brimonidine, or similar agents within 2 weeks prior to the trial; 6) Chemical peel treatments within 2 weeks prior to the trial; 7) Oral retinoid use within 2 months prior to the trial (6 months for acitretin); 8) Topical tacrolimus use within 3 months prior to the trial; 9) Facial energy-based procedures (laser/IPL/RF), injectable treatments (including hydrodermabrasion), or surgeries within 2 months prior to the trial; 10) Emotionally unstable individuals or those with unrealistic outcome expectations; 11) Keloid predisposition, trypanophobia, or inability to comply with follow-up. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-05-01 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-08-20 00:00:00 至 To 2025-09-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机信封法。 由统计人员生成随机序列,将分组结果(实验组/对照组组)打印并密封入不透明信封。每个信封标注唯一编号(与受试者ID对应)。受试者入组时,研究者按编号领取对应信封,当场拆封并执行信封内的分组指令。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomized envelope method: Statisticians generate a random allocation sequence (test group/control group), which is printed and sealed in opaque envelopes, each labeled with a unique subject ID. At enrollment, the researcher opens the corresponding envelope and assigns the subject as indicated inside. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲(对受试者隐藏分组),对评估者隐藏分组 |
|
Blinding: |
Single-blind (group allocation is hidden from participants), group allocation is hidden from evaluators |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
国家生物信息中心(https:/modc.cncb.ac.cnlgsub/),在试验结束6个月内上传试验数据。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
China National Center for Bioinformation(https:/modc.cncb.ac.cnlgsub/), at the end of the test to upload the test data in 6 month. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表和里恩电子采集和管理系统同步进行。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The Trial uses both CRF and EDC for eCRF. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |